Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CNS Therapies Contribute Rising Share Of Breakthrough Designations

Executive Summary

Breakthrough program could speed first treatments for tardive dyskinesia, primary progressive multiple sclerosis, and Parkinson's psychosis to market, along with new fast-acting approaches to treatment-resistant depression.

Advertisement

Related Content

Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
Ocrelizumab May Represent Roche’s Rebound In Neuroscience

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel